Key Points
- CRISPR Therapeutics General Counsel James Kasinger sold 10,400 shares at an average price of $60.24, generating $626,496. Following the sale, he retained 94,784 shares, representing a 9.89% reduction in his ownership.
- CRSP opened at $55.70 and has traded between $44.12 and $78.48 over the past year. The company remains unprofitable, reporting a quarterly loss of $0.94 per share and analysts forecasting a full-year loss of $4.47 per share.
- Wall Street’s consensus rating is “Moderate Buy”, with a $67.94 average price target; institutional investors own approximately 69.2% of the stock.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 10,400 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total transaction of $626,496.00. Following the transaction, the general counsel owned 94,784 shares in the company, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
CRISPR Therapeutics Price Performance
CRISPR Therapeutics stock opened at $55.70 on Friday. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $78.48. The firm has a 50 day moving average price of $53.63 and a 200 day moving average price of $52.75. The company has a market cap of $5.39 billion, a price-to-earnings ratio of -11.70 and a beta of 1.76. The company has a debt-to-equity ratio of 0.34, a quick ratio of 17.85 and a current ratio of 17.85.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. The company had revenue of $10.18 million for the quarter. CRISPR Therapeutics had a negative return on equity of 24.39% and a negative net margin of 3,368.72%. Sell-side analysts predict that CRISPR Therapeutics AG will post -4.47 earnings per share for the current year.
Wall Street Analyst Weigh In
CRSP has been the topic of several research reports. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, August 6th. UBS Group set a $80.00 price target on CRISPR Therapeutics in a research report on Friday, June 12th. Citigroup restated a "market outperform" rating on shares of CRISPR Therapeutics in a research note on Tuesday, August 25th. Weiss Ratings restated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of CRISPR Therapeutics in a research note on Monday, August 31st. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $67.94.
View Our Latest Analysis on CRSP
Hedge Funds Weigh In On CRISPR Therapeutics
Hedge funds have recently made changes to their positions in the business. IFP Advisors Inc boosted its position in shares of CRISPR Therapeutics by 29.9% during the 4th quarter. IFP Advisors Inc now owns 1,250 shares of the company's stock valued at $66,000 after purchasing an additional 288 shares in the last quarter. Versant Capital Management Inc boosted its holdings in CRISPR Therapeutics by 175.1% during the second quarter. Versant Capital Management Inc now owns 465 shares of the company's stock worth $25,000 after buying an additional 296 shares in the last quarter. Sunbelt Securities Inc. boosted its holdings in CRISPR Therapeutics by 4.5% during the first quarter. Sunbelt Securities Inc. now owns 7,843 shares of the company's stock worth $373,000 after buying an additional 336 shares in the last quarter. D.A. Davidson & CO. grew its position in CRISPR Therapeutics by 5.9% in the first quarter. D.A. Davidson & CO. now owns 6,324 shares of the company's stock worth $301,000 after buying an additional 353 shares during the last quarter. Finally, Kestra Advisory Services LLC grew its position in CRISPR Therapeutics by 2.0% in the first quarter. Kestra Advisory Services LLC now owns 21,052 shares of the company's stock worth $1,001,000 after buying an additional 416 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.
CRISPR Therapeutics News Summary
Here are the key news stories impacting CRISPR Therapeutics this week:
- Positive Sentiment: Casgevy sales momentum remains a key bullish factor. An analysis highlighted 78% sequential sales growth for Casgevy in the second quarter, reinforcing the therapy’s potential as a major commercial product and supporting a long-term bullish view of CRSP despite a slow initial launch. CRISPR Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
- Positive Sentiment: Institutional interest provides additional support. Fisher Asset Management reported a new position of 77,960 CRSP shares, valued at approximately $4.25 million at the end of the second quarter. The purchase is an older filing and does not necessarily reflect current positioning, but it signals that some professional investors see upside potential. Billionaire Ken Fisher Was Buying These 2 Cathie Wood Stocks
- Positive Sentiment: Analyst optimism remains substantial. One market commentator sees a potential path to roughly 85% upside, citing CRSP’s position in gene-editing medicine and Casgevy’s commercial opportunity. However, the target is speculative and must be weighed against the company’s ongoing cash burn and losses. CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
CRISPR Therapeutics Company Profile
(
Get Free Report)
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines using CRISPR/Cas9 technology. The company's programs are designed to modify disease-associated genes in human cells, with the goal of treating serious conditions across hematology, oncology, autoimmune disease and regenerative medicine.
Its most advanced product is Casgevy (exa-cel), an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals. Casgevy uses CRISPR/Cas9 gene editing to modify a patient's blood stem cells and is approved in several markets for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
